INTRODUCTION
The carbohydrates of glycoconjugates are highly diverse structures with variation in monosaccharide composition, position of glycosidic linkages, and branching of chains (1) . Further diversity is generated by the covalent attachment of sulfate (SO 3 -) to distinct hydroxyl and amino groups in these saccharides (2) . As sulfate modifications can be extensive and tend to occur in clusters in glycoproteins, they can have a profound effect on the physicochemical character of the glycoconjugate, at least in part by conferring a negative charge at physiological pH (3) . In addition, regioselective sulfation of carbohydrates frequently generates specific epitopes that can be recognized by hormones, extracellular matrix proteins, cell surface receptors, and viruses (2) (3) (4) .
In this context, sulfation of carbohydrates has been shown to be a critical structural requirement of the ligand determinants recognized by the leukocyte adhesion molecule L-selectin (5, 6) . L-selectin is a lectin-like cell adhesion molecule that mediates tethering and rolling of lymphocytes along high endothelial venules (HEV) 1 , which is the first requisite step in the process of lymphocyte extravasation into lymph nodes (7, 8) . 6-O-Sulfation on galactose and N-acetylglucosamine (i.e. GlcNAc-6-SO 4 and Gal-6-SO 4 ), which is found in the context of sialyl Lewis x, is necessary for high affinity binding between L-selectin and these HEV-associated ligands (9) .
These observations prompted considerable interest in the molecular identification of the sulfotransferase enzymes that facilitate 6-O-sulfation at Gal or GlcNAc within mucin-type acceptor saccharides. Habuchi and colleagues first cloned avian chondroitin 6-O-sulfotransferase (C6ST), which facilitates 6-O-sulfation of GalNAc in chondroitin (10) . These workers then showed that the same enzyme can also add sulfate to the 6-hydroxyl group of Gal in sialyl N-acetyllactosamine, a structure known to occur in HEV-associated ligands (11) . In order to identify novel Gal or GlcNAc 6-O-sulfotransferases in human and mouse, we performed homology searches (BLAST) on appropriate databases for expressed sequence tags (ESTs) homologous to avian C6ST. The ESTs retrieved in our searches mapped to four separate genes, which we have termed GST1 through GST4 (GST = Gal/GalNAc or GlcNAc 6-O-sulfotransferase). Full length human cDNAs and genomic DNAs for all four human genes and their mouse homologues have been cloned and expressed (12) (13) (14) (15) (16) (17) (18) Hemmerich et al., submitted) . Human and mouse homologues of the avian C6ST gene (termed GST0 in our nomenclature) have also been reported (19, 20) . All five genes encode highly homologous type II transmembrane proteins with a predicted single pass transmembrane domain, a cytosolic tail, and a catalytic domain residing in the lumen of a Golgi compartment.
The enzymatic activities and substrate specificities of these proteins were determined using glucosaminoglycans (GAGs) or synthetic oligosacharides as acceptors (12, 14, 21, Bowman et al., submitted) and/or cotransfected recombinant ligand glycoproteins (16) (17) (18) . While C6ST was found to add sulfate to the 6-position of N-acetylgalactosamine in chondroitin or galactose in keratan sulfate and sialyl N-acetyllactosamine (10, 11, 19, 20, 22) , GST-1 specifically catalyzed 6-O-sulfation of galactose in keratansulfate or GlyCAM-1 (12, 16) and has been named keratan sulfate 6-O-sulfotransferase (KSGal6ST) (12) or carbohydrate sulfotransferase-1 (CHST-1) (15) . In contrast, the other three enzymes, GST-2, -3, and -4, were found to facilitate 6-O-sulfation of GlcNAc (14, (16) (17) (18) . Based on their respective substrate specificity and tissue restriction, these enzymes have also been named N-acetylglucosamine 6-Osulfotransferase (ubiquitously expressed GlcNAc6ST) (13, 14) , high endothelial cell N-acetylglucosamine-6-O-sulfotransferase (HEC-GlcNAc6ST) (16) also known as LSST (17) , and intestinal Nacetylglucosamine-6-O-sulfotransferase (I-GlcNAc6ST) (18) , respectively (nomenclature reviewed in ref. 23 ).
been reported to direct expression of L-selectin ligands in cells expressing core-2 linked sialyl Lewis x, with GST-1 and GST-3 synergizing in directing expression of high affinity L-selectin ligands (16, 17, 25) .
The identity of a putative high endothelial cell galactose 6-O-sulfotransferase that is predicted to be functional in biosynthesis of 6'-sulfo sialyl lactosamine or 6'-sulfo sialyl Lewis x in HEV-associated Lselectin ligands has remained obscure. We have therefore continued to screen databases for ESTs that may map to novel GST-genes. In this search we have found an open reading frame predicted to code for a novel member of the GST-family on a human genomic DNA clone from chromosome Xp11 (Genbank accession number AL022165). A human cDNA containing the same open reading frame has very recently been reported to encode a novel N-acetylgalactosamine 6-O-sulfotransferase termed chondroitin 6-sulfotransferase 2 (C6ST-2) (26) (Genbank accession no. AB037187). We have named the novel enzyme GST-5 and characterized its enzymatic activity and acceptor specificity on synthetic oligosaccharide substrates as well as by co-transfection with the recombinant mucin GlyCAM-1. In our hands GST-5 catalyzes 6-O-sulfation at GlcNAc in oligosaccharide substrates as well as GlyCAM-1 and does not act on simple GalNAc glycosides. We have also identified a GST-5 homologous open reading frame in the mouse genome and mapped it to mouse chromosome X at band XA3.1-3.2.
EXPERIMENTAL PROCEDURES

Materials.
The following commercial materials were used: carrier-free [ 35 S]PAPS was either synthesized as described previously (27) or obtained through custom synthesis by NEN Life Science Products. Restriction enzymes, T4 polynucleotide kinase, and Taq-polymerase were from Boehringer Mannheim unless specified otherwise. Pfu-polymerase was from New England Biolabs. Tissue culture reagents were purchased from Life Technologies. Commercial plasmids were from Invitrogen. All other chemicals were from Sigma. All of the benzyl glycosides examined for suitability as substrates (Fig. 7) except for GalNAcβ1→ΟBn were all purchased from Sigma. The latter was synthesized as described below. Our disaccharide neoglycolipid substrate for sulfotransferases, GlcNAcβ1→6Galα1→N-octylpropanamide (disaccharide) was synthesized as described elsewhere (21) using a procedure modified from the synthesis reported previously (27) . Our trisaccharide acceptor Galβ1→4GlcNAcβ1→6Galα1→ N-octylpropanamide was generated enzymatically from the disaccharide as described (27) . All three neoglycolipid substrates (including GlcNAcβ1→O(CH 2 ) 7 CH 3 , cf. below) were purified by C 18 reverse phase HPLC (Varian Dynamax 100A) using a water acetonitrile gradient (10-60% CH 3 CN) at a flow rate of 10 ml/min.
H-NMR and mass spectroscopy.
1 H NMR spectra were recorded at 300, 400, or 500 MHz on a Bruker AMX or DRX NMR spectrometer, and 13 C spectra were recorded at 75, 100, or 125 MHz on the same spectrometers at the University of California, Berkeley NMR facility. Spectral data are tabulated as chemical shifts in ppm (δ) downfield from tetramethylsilane, followed by multiplicity (s, singlet; d, doublet; dd, doublet of doublets, t, triplet; m, multiplet), integration, and coupling constant(s) (J) in Hz. Liquid secondary ion mass spectra (LSIMS) and electrospray ionization (ESI) mass spectra were obtained at the University of California, San Francisco Mass Spectrometry Facility.
Benzyl 3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-β-D-galactopyranoside.
To a flask containing 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-galactopyranoside (0.50 g, 1.3 mmol) under Ar was added 13 ml of dichloroethane. The solution was cooled to 0 °C and to it was added trimethylsilyl trifluoromethanesulfonate (TMSOTf) (0.26 mL, 1.4 mmol). After stirring for 10 min, the solution was heated to 50 °C for 18 h. Activated 4 Å molecular sieves were added and the mixture was stirred for 1 h. Distilled BnOH (1.3 mL, 13 mmol) was added and the reaction mixture was stirred for 48 h. Triethylamine (0.5 mL) was added and the mixture was stirred for 1 h. The solution was filtered through Celite, rinsing with 1:1 CHCl 3 /MeOH. The crude product was concentrated and purified by silica gel chromatography eluting with a gradient of 100:1 to 10:1 CHCl 3 /MeOH to yield 0.37 g (65%) of a clear gel. 1 
Benzyl 2-acetamido-2-deoxy-β-D-galactopyranoside.
To a flask containing benzyl 3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-β-D-galactopyranoside (0.11 g, 0.25 mmol) was added 3 mL of MeOH and 1 mL of a 0.1 M solution of NaOMe in MeOH. The solution was stirred for 18 h, then passed through a column of Dowex AG 50w-X2 cation exchange resin (H + form) and concentrated. The product was purified by HPLC and lyophilized to yield 64 mg (82%) of a white powder. 1 
Plasmids.
A kanamycin resistant E. coli stab culture harboring a P1-derived artificial chromosome (PAC) containing human genomic clone 71L16 (Genbank accession no. AL022165) from genomic library RPCI-1 was obtained from the Sanger Centre, Cambridge, UK. PAC-DNA was prepared using the KB100 plasmid kit (Genome Systems) according to the manufacturer's specifications. An ampicillin resistant E. coli glycerol stock harboring a plasmid containing IMAGE clone 2106380 (Genbank accession no. AI419198) in the vector pT7T3D-Pac was obtained from Research Genetics, Huntsville, AB). Plasmid DNA was prepared using the Qiaprep 500 plasmid kit (Qiagen).
Northern blot analysis.
A 368 bp fragment corresponding to nt 238-605 in the human GST5 ORF (Fig. 1) was labeled with [α-32 P]dATP (Amersham Pharmacia Biotech) and used to probe Northern blots of various human tissue RNAs (Human Multiple Tissue Northern Blots, Clontech) as previously described (16) . The blot was then stripped and rehybridized with a probe for actin mRNA as described (16) .
Construction of expression vectors.
Full length human GST-5: The incomplete GST-5 cDNA (2061 bp) contained in the above IMAGE plasmid (AI419198) was excised with Not I and EcoR I and ligated into pCDNA3.1(+) between Not I (5') and EcoR I (3'). For 5'complementation of this cDNA as predicted by the genomic ORF (Genbank accession no. AL022165) the following complementary oligonucleotides were synthesized: 5'-GGCCGCAAGCTTATGAAGGGCCGGCGGCGGCGACGCCGAGAGTACTGCAAGTTCGCGCT GCTGTTGGTGCTGTACACGCTGGTGCTGTTGCTCGTCCCCTCCGTATTGGACGGC-3', 5'-GGCCGCCGTCCAATACGGAGGGGACGAGCAACAGCACCAGCGTGTACAGCACCAACAGC AGCGCGAACTTGCAGTACTCTCGGCGTCGCCGCCGCCGGCCCTTCATAAGCTTGC-3'. These oligonucleotides were annealed, 5'-phosphorylated, and ligated into the Not I site of above plasmid pCDNA3.1(+)AI419198, using established techniques (28) . The resulting expression plasmid pcDNA3.1(+)FLhuGST5 was sequenced on both strands between the 5' Not I site and the 3' EcoRI site. The sequence of the 2152 bp full length human GST-5 cDNA contained in this expression plasmid is identical to the sequence reported by the Sugahara team (26) . GlyCAM-1-IgG: the expression plasmid encoding the GlyCAM-1/IgG chimera has been described previously (16) .
In order to direct secretion of recombinant soluble GSTs bearing N-terminal His 6 -tags, a modified pSecTagHis vector was constructed that possessed a His 6 epitope tag encoding sequence immediately following the IgK secretion signal and preceding the multiple cloning site. This design provided for the expression of a secreted protein with an N-terminal His 6 tag. The pSecTagHis vector was derived from the commercial pSecTag2A vector as follows: a PCR product was amplified from the commercial vector using primers, 5'-CGGGAGATCTCCCGATCCCCTATGG-3', and 5'-CGCGGGATCCATGATGATGATGATGATGGGCCGCGTCACCAGTTGGAACCTGGAACC-3'. This amplicon as well as the template vector pSecTag2A were digested with Bgl II and BamHI, then the amplicon was ligated back into the vector yielding the modified expression vector pSecTagHis.
Plasmid directing secretion of soluble human GST-5: a cDNA fragment encoding residues 32 through 486 of human GST5 was amplified from the 71L16 PAC DNA using primers, 5'-CAGCCCAGTGTGGTGGGACGGCGGCCGCGACGGGGAC-3' and 5'-GCTGCCACTGTGCTGGCTACGTGGCGCCGTCGGCATC-3'. PCR amplification was carried out with Pfu polymerase (Stratagene) at 94˚C for 3 min, with 35 cycles of 94˚C for 1 min, 60˚C for 1 min, and 72˚C for 2 in 7% (v/v) DMSO. The resulting amplicon was purified using MoBio Ultraclean PCR Cleanup kit, digested with BstX (New England BioLabs), and ligated into the BstX-site of the modified expression vector pSecTagHis (described above). The final construct pSecTagHis 6 GST5 was sequenced along both strands and found to encode a fusion protein in which the peptide METDTLLLWVLLLWVPGSTGDAAHHHHHHGSTPVWW was fused to the N-terminus of the luminal domain of human GST-5 (aa 32-486).
Plasmids for expression of soluble human GST-2 and GST-3 in insect cells: an N-terminal truncated fragment of GST2 ORF was amplified from a GST2 cDNA (Genbank accession no. AF083066) by PCR using primers: 5-GCGGTACCATCCTGGCAATGGCACTCGGGGCACCGGGGGC-3'; 5-GCGTCGACGAGACGGGGCTTCCGAAGCAGGGTCTTGC-3'. An N-terminal truncated fragment of GST3 ORF was amplified from a GST3 cDNA (Genbank accession no. AF131235) (16) by PCR using primers:
The PCR products were digested with Kpn I and Sal I and ligated into the pCDNA3.1/HisA. The resulting vectors pCDNA3.1-GST2-His 6 and pCDNA3.1-GST3-His 6 were confirmed by double strand sequencing across the junctions and the entire inserts. The GST2-His 6 and GST3-His 6 inserts from these vectors encoding N-terminal truncated and C-terminal His 6 epitope-tagged GST-2 or GST-3 (resp.) were then excised with Kpn I and Xho I and subcloned between these sites in the baculovirus expression vector pMelBac. Recombinant baculovirus stocks were generated and titers measured using established procedures.
Cloning of mouse GST-5 from a BAC library.
A Hind III/BamH I fragment (1390 bp) of pT7T3D-Pac-AI419198 comprising most of the ORF and 24 bp of 3' UTR of human GST5 was provided to Genome Systems Inc. for hybridization screening on a mouse C57Bl/6 mouse genomic BAC library (pBeloBac11 vector). DNA was generated and isolated from the BAC clones as decribed above. Sequencing of the mouse GST5 ORF within this BAC was commenced with the primer 5'-CCCGGACGTTTTCTACTTGT-3' (positions 372-392 of human GST5 ORF) derived from a region expected to be highly conserved across isozymes and species) (23) . The sequence generated with this primer was then used for further synthesis of mouse GST5 specific primers, and in this fashion the entire mouse GST5 ORF as well as >100 bp of 5' and 3' adjacent sequence were determined (Genbank accession no. AF280089). This sequence as well as the mouse GST-5 amino acid sequence predicted by the long (1455 bp) ORF is depicted in Fig. 1 .
Chromosomal localization of mouse GST5 by fluorescence in situ hybridization.
DNA from above msGST5 BAC was labeled with digoxigenin dUTP by nick translation. Labeled probe was combined with sheared mouse DNA and hybridized to normal metaphase chromosomes derived from mouse embryo fibroblast cells in a solution containing 50% formamide, 10% dextran sulfate and 2X SSC. Specific hybridization signals were detected by incubating the hybridized slides in fluoresceinated antidigoxigenin antibodies followed by counterstaining with DAPI. The initial experiment resulted in specific labeling of the proximal region of a medium sized chromosome, which was believed to be the X chromosome on the basis of DAPI staining. A second experiment was conducted, in which a probe which is specific for the telomeric region of the X chromosome was cohybridized with msGST5 BAC DNA. This experiment resulted in the specific labeling of the telomere and the proximal portion of the X chromosome. Measurements of 10 specifically labeled X chromosomes demonstrated that msGST5 is located at a position which is 11% of the distance from the heterochromatic-euchromatic boundary to the telomere of the X chromosome, an area that corresponds to band XA3.1-3.2. A total of 80 metaphase cells were analyzed with 70 exhibiting specific labeling.
Transient co-expression of full-length GST5 with GlyCAM-1/IgG. COS-7 cells were grown to 80% confluency in a T162 culture flask (Corning-Costar, Corning, NY) and transfected with 8 µg of a plasmid encoding GlyCAM-1/IgG and 8 µg of pCDNA3.1 encoding either GST-5, or lacZ (mock control) using Lipofectamine (Life Technologies) in Opti-MEM (Life Technologies) according to the manufacturer's protocol. Recombinant GlyCAM-1/IgG was isolated as described previously (16) . 1% of each protein sample was analyzed by SDS-PAGE and the remaining samples were lyophilized for subsequent acid hydrolysis and analysis.
Analysis of Sulfated GlyCAM-1/IgG Carbohydrates.
The lyophilized recombinant GlyCAM-1/IgG samples were subjected to partial acid hydrolysis, size and charge fractionation, and subsequent analysis by high pH anion exchange chromatography (HPAEC) essentially as described previously (16) . The second step in fractionation of the hydrolysate was altered slightly: instead of continuous elution with a rising gradient of pyridine-acetate, the column was eluted in two steps of 10 ml (two column volumes) 100 mM pyridine acetate pH 5.4. The first and second eluate were separately lyophilized and analyzed by high pH anion chromatography. HPAEC was carried out on a Dionex DX500 chromatography analysis system with a Carbopac 1 column (Dionex Corp.) and a Packard Radiomatic online Scintillation counter. The column was eluted isocratically with 150 mM NaOH in 400 mM NaOAc at 1 ml/min. Carbohydrate standards were detected by pulsed amperometry. For detection of radioactivity the eluate was sampled on line every 6 seconds. The lag between the amperometric detector and the scintillation detector was determined as 0.4 min by comparing the elution time of galactose 6-sulfate and [
3 H]-galactose 6-sulfate in the same run. The elution times used in figure 4b are those measured or calculated for arrival at the scintillation detector.
Transient Expression of soluble GST-5.
COS-7 were grown to 60% confluency in a T225 culture dish (Corning-Costar, Corning, NY) and transfected with 25 ug plasmid pSecTagHis-GST5 using Lipofectamine (Life Technologies) in Opti-MEM (Life Technologies) according to the manufacturer's protocol. Soluble GST-5 was isolated from the conditioned medium after 4 days as described below.
Expression of recombinant soluble GST-2 and GST-3.
Sf9 insect cells were grown in TNM-FH medium infected with the appropriate recombinant baculovirus. Three days post-infection cells were sedimented (10 min at 2000 x g) and supernatant was concentrated 12-fold, filtered and dialyzed against 20 mM Tris, pH 8.0, 100 mM NaCl. The enzymes were then purified from the dialyzed concentrate as described below.
Purification of His 6 -tagged recombinant enzymes.
The crude enzyme preparations were dialyzed against 50 mM sodium phosphate pH 8.0 supplemented with 150 mM NaCl and 5 mM imidazole, and loaded onto a nickel-nitrilotriacetic acid affinity resin superflow column (Qiagen, 10 ml bed volume) equilibrated in 50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 10 mM imidazole. The column was washed with 30 column volumes of 50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 20 mM imidazole, then bound protein was eluted with three column volumes of 50 mM Na-phosphate, pH 8.0, 300 mM NaCl, 250 mM imidazole, and then with another three column volumes of 50 mM Na-phosphate, pH 8.0, 300 mM NaCl, 500 mM imidazole. Fractions were assayed for sulfotransferase activity and active fractions pooled and concentrated into a final volume of 0.3 ml by ultrafiltration (Centricon 30, Amicon). Total protein concentration was measured using Bradford protein assay kit (BioRad). The measured protein concentrations were always higher than enzyme concentrations because of the presence of contaminants (cf. Fig. 5 ). The concentrated enzyme preparations were supplemented with 10% glycerol, aliquotted, snap-frozen in liquid N 2 , and stored at -70˚C for use in sulfotransferase assays. For SDS-PAGE of GST-5 an aliquot of each pertinent column fraction was concentrated to a degree that the total protein concentration became ~0.1 mg/ml. 2 x 16 µl (1.6 µg) of each fraction were loaded onto two parallel 10% polyacrylamide mini-gels (Novex). One gel was stained with colloidal Coomassie Blue G250 (Novex). The other gel was transferred onto nitrocellulose. The blot was probed with anti-His 6 antibody (HisG, Invitrogen, 0.2 µg/ml) and then with horse-radish peroxidase conjugated sheep anti-mouse Ig (Amersham). The blot was then developed using the ECL Western Blotting Detection System (Amersham) according to the manufacturer's instructions.
Sulfotransferase assays using benzyl glycosides.
Standard assay reactions of 50 µl were carried out in 96 well plates at pH 6.5 in buffer ST (30 mM HEPES, 1% Triton-X-100, 4 mM Mg(OAc) 2 , 10 mM NaF, 1 mM ATP, 10% glycerol) with 1 mM benzyl glycoside substrate, 2 µM [ 35 S]-PAPS (6000 Ci/mol) and 1 µl of enzyme (~0.05 µg total protein, cf. above). Reactions were incubated overnight at 25°C, then quenched with two volumes of 100% MeOH. A 50 µl aliquot of each reaction was spotted at the bottom of each channel on a 19-channel silica gel 60 Å TLC plate (Whatman). Plates were developed in BuOH:EtOH:H 2 O (6:3:2). The plates were then dried and exposed with phosphor-screen (Molecular Dynamics). Screens were scanned in a Storm 860 phosphor-imager (Molecular Dynamics). Sulfate incorporation was calculated as the ratio of the area under the product peak to the sum of the areas under all peaks using ImageQuant software (Molecular Dynamics).
Sulfotransferase assays using synthetic glycolipids. Assays were performed in 96-well plates using neoglycolipid acceptors (1 mM), [ 35 S]-PAPS (2.5 µM, 2.5 µCi/ml), ATP (1 mM), and 1 µl of enzyme in 30 mM HEPES pH 6.5, 4 mM Mg(AcO) 2 , 10 mM NaF, 10% Glycerol, 1% Triton X-100. Reaction mixtures (20 µl) were incubated overnight at 25°C. Reactions were stopped with the addition of 100 µl of distilled water. Reactions were then transferred from the 96-well plate to preconditioned Oasis HLB reversed-phase extraction plates (Waters) and washed with distilled water. The radiolabeled substrate was eluted with 200 µl/well methanol and the plates were air dried. The amount of radioactivity incorporated into the substrate was determined by scintillation counting. Reactions were run in duplicate. Background (always <500 cpm) was determined by omission of the oligosaccharide acceptor from the reactions mixture and subtracted from the signal measured with acceptor. Determination of the position of the [
35 S]-sulfate ester in the disaccharide sulfated by GST-5 was performed as previously described (27) .
RESULTS
Identification of an open reading frame encoding a novel Gal/GalNAc/GlcNAc 6-O-sulfotransferase (GST) on the human X chromosome.
The Genbank nr and dbEST databases were probed with the protein sequence of human HECGlcNAc6ST (GST-3) using the tBLASTn algorithm (29) . This search identified a 1461 bp open reading frame (ORF) in a genomic sequence from human chromosome Xp11 contained within PAC clone 71L16 (Genbank accession number AL022165). This clone is from the library RPCI1 constructed at the Roswell Park Cancer Institute by the group of Pieter de Jong. The 1461 bp ORF includes nt 55281 through 56741 of the 176 kb genomic sequence, is located 100 kb upstream of genomic marker DXS1003 (position 156271 through 156567), and is annotated in the pertinent Genbank entry (AL022165) as a "putative chondroitin 6-O-sulfotransferase-like gene". The start codon ATG of this ORF fulfills the Kozak requirements (30) and is preceded in the genomic sequence by an inframe stop codon located 3 bp 5' to the start codon. The 486 bp polypeptide predicted by this ORF is a typical type II transmembrane protein with 43.8 % similarity and 35.7 % identity to human GST-3. We termed this gene GST5 and the predicted sulfotransferase enzyme GST-5. Kitagawa and coworkers have recently reported the same protein sequence as chondroitin 6-sulfotransferase 2 (26) (Genbank accession no. AB037187).
Identification of partial cDNAs coding for GST-5.
Screening of the Genbank dbEST database with the GST5 ORF (BLASTn) yielded two matching ESTs derived both from human glioblastoma (Genbank accession numbers AI088880 and AI419198). These were found to be partial cDNAs mapping to GST5 with the 5' ends of both inserts being located at a Not I site located at position 101 of the GST5 ORF. Genbank EST clone AI419198 was fully sequenced: its 2052 bp contain a 5'-incomplete open reading frame of GST5 from the Not-I site at position 101 through the stop codon followed by a 3' untranslated region (UTR) with a polyadenylation signal followed by a poly A tail.
Generation of a full length GST-5 cDNA expression cassette.
The insert from EST clone AI419198 was subcloned into the expression vector pCDNA3.1+, then a synthetic oligonucleotide containing the first 108 bp of the GST5 ORF contained in genomic clone 71L16 (from start ATG to the Not I site) was ligated in into the 5' Not I site of the resulting plasmid pCDNA3.1-AI419198. The sequence of the resulting complete cDNA insert (5'ATG through poly A tail) was determined and found to be identical to the cDNA sequence of human chondroitin 6-O-sulfotransferase recently reported by the Sugahara group (26) .
Identification of a murine ORF encoding a mouse homologue of GST-5.
A 1390 bp fragment of human GST5 cDNA including most of the ORF plus 24 bp of 3'UTR was used to screen a genomic BAC library from C57Bl/6 mouse. The probe was found to hybridize to a single BACclone. The genomic mouse sequence within this BAC contained a long ORF of 1455 bp (Genbank accession no. AF280089). This ORF encoded a 484 aa type II transmembrane protein with 87.8% identity to human GST-5. The predicted enzyme was termed mouse GST-5 and its cDNA and amino acid sequences are depicted and compared to the amino acid sequence of its human homologue in Fig. 1 .
Chromosomal localization of the mouse GST5 gene.
Fluorescence in situ hybridization analysis (FISH) revealed that the mouse GST5 gene is located in between bands A3.1 and A3.2 on the mouse X chromosome (Fig. 2) .
Expression of human GST5.
The expression of GST-5 in human tissue was investigated by Northern Analysis. As show in Fig. 3 , low amounts of transcripts corresponding to this gene were found in most tissues examined, however, relatively high levels of GST5 mRNA were detected in liver, heart and spleen.
GST-5 catalyzes sulfation at the 6-hydroxyl group of GlcNAc in the mucin-type glycoprotein GlyCAM-1.
To confirm that GST5 encoded a sulfotransferase, we transfected COS-7 cells with a cDNA encoding a GlyCAM-1/IgG chimera and the pCDNA3.1-GST5 expression cassette described above. GlyCAM-1 is one of the mucin-like ligands for L-selectin that are expressed in HEV. We have previously used this IgG chimera of GlyCAM-1 to characterize the sulfotransferase activities of GST-1, 2, 3, and 4 (16,18, Bhakta and Hemmerich, unpublished results). The transfected COS-7 cells were cultured in the presence of [ 35 S]-sulfate. GlyCAM-1/IgG was purified from the conditioned medium on protein A-agarose and analyzed by SDS-PAGE and autoradiography. As shown in Fig. 4a , there was about four-fold elevated incorporation of [ In order to establish the regiochemistry of the sulfation reaction, the radiolabeled GlyCAM-1/IgG obtained in above experiment was subjected to hydrolysis and Dionex HPLC analysis according to our previously established procedures. As shown in Fig. 4b , transfection with GST5 resulted in products that corresponded to [O 3 SO→6]GlcNAc and Galβ1→4[O 3 SO→6]GlcNAc. Thus, this enzyme was established to be a novel GlcNAc 6-O-sulfotransferase.
Expression and purification of soluble recombinant human GST-5.
In order to demonstrate the sulfotransferase activity of GST-5 in a cell free system and investigate its acceptor specificity further, we expressed the portion of the gene presumed to encode the sulfotransferase domain in a soluble epitope tagged form in COS7 cells. We replaced the 32 residues at the N-terminus of GST-5 (the predicted cytoplasmic and transmembrane domains, cf. Fig 1) , with a His 6 -tag in the modified vector pSecTagHis. This plasmid directs secretion of an N-terminal His 6 -tagged soluble GST-5 into the conditioned medium after cleavage of the Igκ signal peptide. The recombinant soluble enzyme was isolated from the conditioned media of the transfected COS-7 cells by affinity chromatography on a Ni 2+ column. On reducing SDS-PAGE the recombinant protein migrated as a diffuse band at an apparent molecular weight of ~50 kDa (Fig 5a) . On a Western blot antibodies specific to the His 6 epitope tag strongly stained this band (Fig. 5b) .
GST-5 catalyzes sulfation at the 6-hydroxyl group of GlcNAc-β but not GalNAc-β in benzyl-glycosides.
The purified recombinant GST-5 was examined and compared to GST-2 and GST-3 for its ability to catalyze sulfation of a number of simple benzyl glycosides, as described in the experimental section. As shown in Fig. 6 , GST-5 imparted sulfation onto GlcNAcβ1→OBn and GlcNAcβ1→4GlcNAcα1→OBn but not onto GalNAcβ1→OBn or GalNAcα1→OBn. The other two N-acetylglucosamine 6-Osulfotransferases, GST-2 and GST-3, exhibited very similar patterns of acceptor specificity with these simple benzylglycosides.
GST-5 catalyzes sulfation at C-6 of GlcNAc in synthetic glycolipid acceptors.
The purified recombinant GST-5 was also compared to soluble forms of the isozymes GST-2 and GST-3 for its ability to transfer sulfate from [ 35 S]-PAPS onto GlcNAc in three synthetic neoglycolipid substrates, GlcNAcβ1→O(CH 2 ) 7 CH 3 (monosaccharide), GlcNAcβ1→6Galα1→(CH 2 ) 2 CONHC 8 H 17 (disaccharide) and Galβ1→4GlcNAcβ1→6Galα1→(CH 2 ) 2 CONHC 8 H 17 (trisaccharide). We have used the latter two synthetic oligosaccharide substrates previously in measuring a GlcNAc 6-O-sulfotransferase activity in porcine lymph nodes (27) . As shown in Fig. 7a , GST-5 sulfated the monosaccharide acceptor as efficiently as GST-2 and somewhat less efficiently than GST-3. The activity of GST-5, GST-3, and GST-2 on the disaccharide and trisaccharide acceptors was then compared and normalized to the activity of these enzymes on the monosaccharide. As shown in Fig. 7b , GST-3 efficiently sulfated the disaccharide containing a terminal GlcNAc at its non reducing end, but was unable to sulfate the internal GlcNAc in the trisaccharide, in agreement with previously reported observations (17, 27) . In contrast, GST-2 sulfated the trisaccharide about 4-fold less efficiently than the disaccharide acceptor. While not strictly requiring a terminal GlcNAc, GST-5 demonstrated a greater preference for this structure than did GST-2 (Fig. 7b) .
DISCUSSION
We report here the cloning of a full-length cDNA from the human X chromosome that encodes a novel human carbohydrate sulfotransferase. We also present the sequence of a highly related X-linked mouse gene, which is likely to encode the mouse orthologue. The cloning was based on a genomic approach in which we screened genomic databases for sequences related to the HEC-GlcNAc6ST. The novel human gene was identified in a 223 kb human genomic DNA fragment from the X chromosome that had been deposited in the Genbank database. A full-length cDNA was generated by synthetic 5' complementation of a 3' polyA+ EST containing a 5' incomplete ORF from this gene. The predicted protein, GST-5, is identical to the recently reported chondroitin 6-sulfotransferase 2 (26) . Thus GST-5 is a type II transmembrane protein with a short cytoplasmic tail, features that are typical of tyrosyl protein and carbohydrate sulfotransferases (4) . Consistent with the cloning strategy, GST-5 is clearly a member of the Gal/GalNAc/GlcNAc 6-O-sulfotransferase (GST) family (23) .
GST-5 has been expressed and characterized by Kitagawa and colleagues as a sulfotransferase catalyzing sulfation at the 6-hydroxyl group of GalNAc in chondroitin (26) . This was determined using in vitro assays in which soluble GST-5 was incubated with polymer chondroitin and other GAGs. Only chondroitin incorporated significant amount of [
35 S]-sulfate, and the incorporated sulfate was assigned as GalNAc-6-O-sulfate by virtue of its susceptibility to hydrolysis by chondro-6-O-sulfatase but not chondro-4-O-sulfatase. By contrast, GST-5 did not catalyze sulfation of GalNAc in the simple GalNAc(α/β)1→ΟBn glycosides used in our analysis. However, in our hands GST-5 efficiently sulfated the 6-hydroxyl of GlcNAc in GlcNAcβ1→ΟBn and GlcNAcβ1→6GlcNAcβ1→ΟBn, but not in Galβ1→4GlcNAcβ1→ΟBn. Thus GST-5 catalyzed 6-O-sulfation of terminal GlcNAc and to a much lesser degree of internal GlcNAc in synthetic mono-and oligosaccharide acceptors. More significantly, when co-expressed with the recombinant mucin GlyCAM-1/IgG, GST-5 efficiently sulfated exclusively at the 6-hydroxyl group of GlcNAc in the O-glycans contained in this mucin. There are several possible explanations for these discrepancies. The GalNAc 6-O-sulfotransferase activity of GST-5 may require the GalNAc to be contained within a GAG such as chondroitin. Alternatively, the chondroitin used as substrate may have included some GlcNAc-containing GAG components. As shown elsewhere (23, Hemmerich et al., submitted), the amino acid sequence of GST-5 is more similar to other GlcNAc 6-Osulfotransferases such as GST-2, -3, and -4, than it is to chondroitin 6-sulfotransferase 1 (GST-0). Finally, it is conceivable that GST-5 can sulfate GalNAc in chondroitin as well as GlcNAc in nascent mucin acceptors, similar to what has been observed for GST-0 which catalyzes 6-O-sulfation of GalNAc in chondroitin (10, 19) as well as 6-O-sulfation of Gal in sialyl N-acetyllactosamine (11) . Additional experiments are required to reconcile our data with those of Kitagawa and colleagues.
The sequence of the putative sulfotransferase domain (residues 100 to 486) is 30-48% identical to other members of the GST family, whereas its homology to other Golgi-associated sulfotransferases of different regioselectivity is less than 20%. The predicted protein sequence of GST-5 contains the same three regions of high sequence conservation (50-95%) with the other members of the GST family that have been identified previously (4, 16, 18, 26) . Two of these regions likely constitute the binding site for the universal sulfate donor PAPS (31) , while the functional relevance of the most C-terminal consensus region remains to be determined. In the mouse genome, we have identified a long open reading frame encoding an enzyme that is 88 % identical to human GST-5. It is unclear as yet, whether this ORF is expressed, since we were unable to retrieve mouse ESTs that map to this ORF. A distinct feature of GST-5 strictly conserved between mouse and human is its conspicuous highly basic 13 amino acid N-terminal cytoplasmic domain containing a stretch of six arginine residues. Cytoplasmic motifs in Golgi-resident glycosyltransferases have been reported to contribute to sublocalization and retention of these proteins in the Golgi (32, 33) . The significance of this sequence in GST-5 remains to be determined.
Both the human and murine GST-5 genes contain complete intron-less open reading frames encoding the full-length enzymes. We have shown the same genomic organization for GST-3 and GST-4 from mouse and human (16,18, Hemmerich et al., submitted) . Intron-less coding sequences within the genome appear to be characteristic for the GST family, as well as the topologically related β3-galactosyltransferases (34) and the α(1,3)fucosyltransferases (35) .
Three members of the GST family (GST-0, GST-1, and GST-2) are widely expressed in human tissues (12-14,17,20, Bistrup, Lee, et al., unpublished data) . In contrast, GST-3 and GST-4 are highly restricted to high endothelial cells and intestinal tissue, respectively (16, 18) . GST-5 has an intermediate expression profile. In human, the strongest expression of GST-5 transcripts was seen in heart and liver (Fig. 3) . However, low level expression of GST-5 transcript was observed in most tissues examined, except in thymus and in bone marrow. We were unable to confirm the high expression of GST-5 in spleen that was reported by Kitagawa et al. (26) . This discrepancy may be due to the different techniques (Northern Blotting vs. RT-PCR) used in the two studies. Further study is needed to determine GST-5 expression at the cellular level.
We have characterized GST-5 as a fourth N-acetylglucosamine 6-O-sulfotransferase isozyme in the GST family. There appear to be subtle differences in the specificities of these enzymes for oligosaccharide acceptors suggesting divergent biological functions. For example GST-2 appears to be capable of catalyzing 6-O-sulfation of GlcNAc when this monosaccharide unit is located at an internal position rather than the non-reducing terminal of a neoglycolipid acceptor. In contrast, GST-3 strictly requires GlcNAc to be located at the non-reducing end of its substrate. The substrate specificity of GST-5 falls in between GST-3 and GST-2 in that it shows residual activity on internal GlcNAc, however, at much lower level than the same activity of GST-2. The ability of GST-2 and GST-5 to sulfate internal GlcNAc, along with their ubiquitous expression patterns, suggests that both enzymes may be functional in biosynthesis of sulfated glucosaminoglycans bearing internal GlcNAc residues such as keratan sulfate. In contrast, GST-3 may participate exclusively in the synthesis of specific sulfated recognition determinants at or close to the nonreducing end of carbohydrate chains in glycoproteins. Fukuda and coworkers (17) have reported that GST-3 specifically requires Core 2 linked O-glycans in its acceptors while GST-2 can sulfate Nglycans as well. Since our glycoprotein acceptor GlyCAM-1/IgG contains O-linked and N-linked glycans (the latter in its IgG Fc domain), we could not resolve this question with respect to GST5 and GST3. The marked restriction of GST-3 (HEC-GlcNAc6ST or LSST) to high endothelial cells suggests that this enzyme may be functional in the biosynthesis of the L-selectin recognition determinant 6-sulfo sialyl Lewis x in vivo. The structures synthesized by GST-5 in its physiological setting remain to be determined. Capping structures containing GlcNAc-6-O-sulfate, such as 6-sulfo sialyl Nacetyllactosamine or 6-sulfo sialyl Lewis x, are found not only on HEV ligands but also on secreted respiratory mucins in patients suffering from pulmonary diseases associated with abnormal mucus secretion (36, 37) . Since human GST-5 is highly expressed in the liver, it could be the human homologue of the rat liver Golgi N-acetylglucosamine sulfotransferase activity reportedly involved in the synthesis of a Siaα2→3Galβ1→4(SO 4 -6)GlcNAc capping structure which is linked to the mannosyl core of asparagine-linked oligosaccharides (38) . This activity prefers GlcNAc at nonreducing ends. A final definition of the different and perhaps overlapping roles of the four N-acetylglucosamine 6-Osulfotransferase enzymes cloned to date awaits the targeted deletion of these genes in mice.
A characteristic feature of GST-5 is that its gene is residing on the X chromosome in both human and mouse. Of the other three isozymes, GST-2 is encoded in human by a gene on chromosome 11, while the GST3 and GST4 genes are clustered in band q23.1-23.2 on chromosome 16 (Hemmerich et al., submitted) . The physiological relevance of these observations remains to be determined. The human GST5 gene is located in band X11.2-11.4 100 kb upstream from genetic marker DXS1003 (cf. Genbank accession no. AL022165). Putative genes upstream and downstream of the GST5 ORF encode a probable Zinc Finger protein and a putative Na + /H + exchanger protein, respectively. Better characterized genes located near genomic marker DXS1003 include genes for a pair of mono-amine oxidases MAO-A and MAO-B (Genbank accession no. M69226 and M69177), the Norrie disease protein (X65882), the A-raf-1 proto-oncogene serine/threonine protein kinase (U01337), the transcription factor TFE-3 (X96717), synaptophysin (X06389) and the ubiquitin-activating enzyme E1 (X56976) (GeneMap'98) (39) . It remains to be investigated whether GST5 is subject to X inactivation. In mouse, the gene maps to band XA3.1-3.2. Nearby genes within region A of the mouse X chromosome again include genes for murine homologues of MOA-A and B, the Norrie disease protein, A-raf, TFE-3, synaptophysin, and E1 (40) . Mouse chromosomal region XA is therefore syntenic with human chromosomal region Xp11. In mouse, this region has been shown recently to contain a disproportionately high number of genes that can escape X inactivation (41) .
GST-5 is the 19th carbohydrate sulfotransferase and the 6th member of the GST family to be molecularly cloned in human or mouse. Given the great diversity of sulfation modifications within glycoconjugates and the multiple known isozymes catalyzing many of these modifications, it is anticipated that other sulfotransferase genes remain to be identified. The identification of genes encoding novel carbohydrate sulfotransferases should expedite rapid progress in the definition of the biological roles of specific sulfation modifications and the contribution of particular enzymes to these functions. Furthermore, those sulfotransferases critically involved in generation of specific recognition epitopes for receptor ligand interactions may become attractive drug targets in settings where modulation of this receptor ligand interaction may be beneficial.
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